Internal Medicine, Pulmonary Disease · San Francisco, CA
NPI
1891060067
Since 2012
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
400 Parnassus Ave, UCSF Box 0359
San Francisco, CA, 94143
Phone (415) 353-2961
Groups this clinician bills Medicare through
Medicare paid, 2024
$71K
937 services
Medicare patients, 2024
289
Average age 69
Drug cost, 2024
$3.9M
1,804 prescriptions
Company payments, 2025
$48K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nicholas A Kolaitis was code 99233 (hospital e&m - subsequent), 179 times for 39 patients. In total Nicholas A Kolaitis billed 937 services in 24 codes, and Medicare paid $71K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-05-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 179 | 39 | $103.87 | $19K |
| 99215 Office E&M - Established | Facility | 160 | 122 | $117.84 | $19K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 133 | 108 | $14.80 | $1,969 |
| 94016 Pulmonary Function Testing | Facility | 69 | 31 | $21.69 | $1,497 |
| 99214 Office E&M - Established | Facility | 58 | 56 | $76.84 | $4,457 |
| 99152 Anesthesia | Facility | 56 | 46 | $10.41 | $583 |
| 31624 Bronchoscopy | Facility | 55 | 45 | $9.16 | $504 |
| 31628 Bronchoscopy | Facility | 49 | 40 | $150.53 | $7,376 |
| 99215 Office E&M - Established | Office | 35 | 29 | $141.15 | $4,940 |
| 31646 Bronchoscopy | Facility | 31 | 15 | $123.14 | $3,817 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 28 | 24 | $13.44 | $376 |
| 99223 Hospital E&M - Initial | Facility | 19 | 19 | $145.29 | $2,761 |
| 99205 Office E&M - New | Facility | 15 | 15 | $140.62 | $2,109 |
By year: 2022 $66K for 656 services; 2023 $71K for 679 services; 2024 $71K for 937 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nicholas A Kolaitis prescribed most often to Medicare patients was Azithromycin, with 145 prescriptions and refills. In total Nicholas A Kolaitis wrote 1,804 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azithromycin Generic | 145 | 269 | 47 | $1,652 |
| Valganciclovir Hcl Generic | 140 | 197 | 37 | $32K |
| Prednisone Generic | 113 | 204 | 48 | $1,072 |
| Tacrolimus Generic | 97 | 166 | 26 | $8,312 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 71 | 132 | 24 | $329 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 62 | 74 | 25 | $1,721 |
| Omeprazole Generic | 58 | 112 | 21 | $422 |
| Tyvaso Dpi Treprostinil | 55 | 55 | Under 11 | $1.3M |
| Fluconazole Generic | 55 | 131 | 22 | $413 |
| Dapsone Generic | 42 | 104 | 20 | $1,770 |
| Sildenafil Citrate Generic | 41 | 42 | Under 11 | $134K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 40 | 40 | Under 11 | $25K |
| Mycophenolate Mofetil Generic | 38 | 75 | 14 | $3,350 |
| Incruse Ellipta Umeclidinium Bromide | 37 | 39 | Under 11 | $13K |
| Tadalafil Generic | 37 | 44 | Under 11 | $25K |
Brand drugs: - claims; generic drugs: 1,236 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nicholas A Kolaitis $48K ($48K in general payments such as food, travel and fees) from 7 companies. The largest payer was Merck Sharp & Dohme LLC with $28K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.